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An Update on BRAF Inhibitors and Other new Molecular 
Targets for the Treatment of Malignant Melanoma of the skin
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Abstract: Malignant melanoma of the skin originates from mutations in melanocytes and can be lethal if unrecognized or untreated in 
its earlier stages. Deaths from melanoma are increasing in the United States and around the world every year. The available treatments 
produce low rates of response with modest survival impact. Among potential molecular targets under investigation, which are mostly in 
the tyrosine kinase pathway, the BRAF (V-raf murine sarcoma viral oncogene homolog B1) gene is the best studied and most frequently 
reported mutation in melanoma. The molecular targets for melanoma treatment, promising drugs for future melanoma treatment as well 
as the new molecular entities that are approved are reviewed here. Approved by FDA in 2011, vemurafenib (Zelboraf) is the first per-
sonalized targeted therapy for treatment of metastatic melanoma that acts by selectively inhibiting BRAFV600E. This has opened a new 
avenue for the discovery of targeted drug therapies for melanoma based on the principles of pharmacogenomics.
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Introduction
Malignant melanoma, which originates from muta-
tions in melanocytes, is a skin cancer that can be 
lethal, particularly if unrecognized or untreated in its 
earlier stages. Melanoma is characterized by stages 0 
to IV based on the degree of cutaneous penetration, 
radial expansion, regional spread and invasion, and/
or metastasis. While stage 0 melanoma or melanoma 
in situ is restricted to the superficial layers of the epi-
dermis, ie, has not through the basement membrane, 
as the melanoma advances through subsequent stages, 
regional lymph nodes and tissues may be invaded. 
In stage IV melanoma, there is metastasis to distant 
organs and tissues, including the lung, liver, brain, and 
bone. The 2013 American Cancer Society Facts and 
Figures report estimates 76,690 new cases of mela-
noma of the skin and 9,480 deaths from melanoma 
in the United States. These estimates are significantly 
higher than the 2003 American Cancer Society Facts 
and Figures report of an estimated 54,200 new cases 
of melanoma and 7,600 deaths. In 2006, there were 
60,000 new cases of cutaneous melanoma in the 
European Union and 13,000 deaths. The current inci-
dence rates range from 15 to 60 per 100,000 people. 
Although the 2013 American Cancer Society Facts 
and Figures indicates that the 5-year relative survival 
rate for locally involved (early stage) melanoma is 
98%, the 5-year survival rate falls to 15% for meta-
static  melanoma. More than 80% of deaths sby skin 
cancer are due to aggressive metastatic melanoma 
that is resistant to existing therapies.1,2 Both molecular 
genetic factors (eg, 40% of melanoma-prone families 
have a mutation in the growth regulating CDKN2A 
gene) and environmental factors (eg, exposure to 
ultraviolet light and a history of severe sunburn, par-
ticularly early in life) are thought to be responsible for 
increasing risk for the development of melanoma.3–5
Molecular Targets for Melanoma
The current therapeutic options for metastatic malig-
nant melanoma are limited. Until the recent approval 
of the targeted therapy vemurafenib,6 a kinase 
 inhibitor indicated for the treatment of patients 
with unresectable or metastatic BRAFV600E-positive 
melanoma, available treatment options, including 
cytotoxic and immunologic therapies, sometimes 
produced low rates of response with modest sur-
vival impact.  Traditional chemotherapeutic drugs, 
such as  dacarbazine (Objective Response Rate 
(ORR) ∼18%), temozolomide (ORR ∼15%), pacli-
taxel (ORR ∼13%), cisplatin (ORR ∼23%), docetaxel 
(ORR ∼11%), lomustine (ORR ∼13%), or carboplatin 
(ORR ∼16%) offer only limited, short lived benefit 
in a small fraction of patients (ORR overall less than 
25%). Though the combination of drugs like dacar-
bazine with immune boosting drugs like ipilimumab 
have yielded higher 1 year survival rates of 47.3%, 
the three year survival rate remains poor (20.8%), 
reflecting the limited duration of response of such 
immuno-modulatory therapy. In addition, significant 
grade 3 to 4 toxicities are observed in a large fraction 
of patients (56.3%).7
A better understanding of the underlying molecu-
lar changes in spontaneous malignant melanoma has 
led to the development of targeted small molecules. 
In particular, the mitogen activated protein kinase 
(MAPK) pathway has been described to be aberrant 
and of oncogenetic relevance in melanoma. However, 
a sole aberration in this pathway, which is also aber-
rant in many benign nevi, has not been described be 
to be sufficient for malignant transformation. Along 
with c-Kit mutations, BRAF (V-raf murine sarcoma 
viral oncogene homolog B1) gene is the best stud-
ied and is reported to be the most frequently mutated 
of all spontaneous metastatic melanomas (about 
50%–70%). In these patients, responses in about half 
of all patients can be observed.
Other potential targets that are being studied 
include components of the Raf/Ras/MAPK pathway, 
phosphoinositide 3-kinase (PI3K)/AKT pathway, 
tyrosine kinases, angiogenesis, poly (ADP ribose) 
polymerases, surviving and heat shock protein 90, 
metastatic pathways, Rho GTPase signaling, integ-
rin activity, and actomyosin contractility.3,8 In some 
investigations, treatments based on two or more 
targets have been considered. For example, NVP-
BEZ235, a potent and stable dual PI3K/mTOR inhib-
itor, has entered Phase I/II clinical trials in patients 
with advanced solid tumors and shows potential in 
the treatment of metastatic melanoma.9 An excellent 
review on emerging molecular targets in melanoma 
invasion and metastasis has been published recently.8
Melanoma and BRAF
Several members of RAS and RAF family in the ERK/
MAPK pathway, including BRAF, NRAS, HRAS 
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and KRAS, undergo mutations and associated with 
melanoma. BRAF, a serine/threonine kinase of the 
RAF family in this pathway, regulates cell growth, 
survival and differentiation and is activated by mem-
brane-bound receptors including tyrosine kinases and 
G-protein-coupled receptors. Mutations in BRAF 
lead to hyper-activation of ERK causing enhanced 
melanoma proliferation and accounts for 50%–70% 
of melanomas.10 The PI3K is another pathway sig-
naled by oncogenic RAS thereby affecting cell prolif-
eration, survival, migration, and invasion. The BRAF 
and NRAS mutations are mutually exclusive.1,11
The most frequent BRAF mutation is a glu-
tamic acid for valine substitution at position 600 
(BRAFV600E) and accounts for .90% of BRAF-
positive mutant melanomas.10,12 Other minor, but 
important mutations that can activate MEK and ERK 
signaling include G465A, K600E, and A727V and are 
thus also important molecular targets in melanoma 
invasion.12–14 Mechanistically, BRAFV600E plays a dual 
role in melanoma initiation and metastatic progres-
sion is the most appealing target for the development 
of drugs to treat primary and metastatic melanoma. 
Several potent BRAF inhibitors have been developed 
as potential treatments for melanoma. However, no 
selective inhibitors of NRAS have been developed. 
Tibifarnib (R115777), a RAS farnesyltransferase 
inhibitor, entered clinical trials but, perhaps due to 
lack of specificity, did not yield promising results. 
However, since RAS is a key element in MEK/ERK 
and PI3K signaling, combination therapies involving 
the inhibitor of these pathways are considered prom-
ising therapeutic options.15,16 A selected number of 
molecularly targeted agents in the treatment of malig-
nant melanoma are summarized in Table 1.
selective BRAF Inhibitors
The structures for selective BRAF inhibitors are 
shown in Figure 1. Vemurafenib (Zelboraf), a 7-azain-
dole derivative, is a highly selective oral, small mol-
ecule, inhibitor of BRAFV600E kinase activity and has 
been recently approved by the US Food and Drug 
Administration (FDA) for the treatment of BRAFV600E 
 mutation-positive melanoma. It is co-developed by 
Roche and Plexxikon, a member of the Daiichi Sankyo 
Group, and is co-promoted in the US by Genentech 
and Daiichi Sankyo. Compared to dacarbazine che-
motherapy, vemurafenib reduced the risk of death by 
56% in patients with previously untreated BRAFV600E 
mutation-positive, unresectable (inoperable) or meta-
static melanoma in the clinical trial. Vemurafenib also 
reduced disease progression or death by 74% com-
pared to those who received chemotherapy.17
PLX4720 is another 7-azaindole derivative that is 
highly selective BRAFV600E kinase inhibitor in both 
biochemical and cellular assays. Thus it potently 
inhibits ERK phosphorylation in BRAFV600E-bearing 
tumor cell lines but not in cells lacking this onco-
genic BRAFV600E. When dosed orally, PLX4720 
caused significant tumor growth delays, including 
tumor regressions, without evidence of toxicity in 
BRAFV600E-dependent tumor xenograft models.18
GDC-0879 is an indane derivative and is highly 
selective, potent, orally bioavailable BRAFV600E kinase 
inhibitor. It is also very effective in reducing cellular 
viability of BRAFV600E-mutant inoperable or meta-
static melanoma cells thus improving the survival of 
the mouse with BRAFV600E tumors.19 AZ628 is a potent 
tyrosine protein inhibitor for wild-type CRAF and 
BRAFV600E and also suppresses activity of VEGFR2, 
DDR2, Lyn, Flt1, and FMS. By causing cell cycle 
arrest, it triggers apoptosis in melanoma cell lines har-
boring BRAFV600E and due to inhibition of VEGFR2 it 
is anti-angiogenic.20 SB590885 is a selective inhibitor 
of BRAF, with significant activity only against CRAF 
and has minimal off-target activity.21
Other Kinase Inhibitors
The structures of several potent kinase inhibitors are 
shown in Figure 2. The biaryl urea derivative sorafenib 
(Nexavar) is a multi-kinase inhibitor that targets both 
wild type BRAF (BRAFWT) and mutated BRAFV600E, 
CRAF, VEGF receptors 1, 2 and 3, PDGF receptor, 
Flt-3, p38, c-Kit, and FGFR-1 and thus inhibits tumor 
growth, angiogenesis and metastatic spread. Its mono-
therapy is inefficient in melanoma possibly due to sur-
vival escape routes provided by other pathways such 
as tumor-necrosis factor-IX when BRAF is inhibited.22 
Regorafenib (BAY 73-4506) is also a multi-kinase 
inhibitor targeting c-KIT, VEGFR2, and BRAF and is 
orally bioavailable. The inhibition of tumor cell signal-
ing kinases (RET, KIT, PDGFR, and RAF) may result 
in the inhibition of tumor angiogenesis and tumor 
cell proliferation and shows potent activity in a wide 
variety of preclinical xenograft models.23 RAF265 
is an oral, highly selective RAF and VEGFR kinase 
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Table 1. A summary of emerging molecularly-targeted agents for melanoma.
Drug/compound Molecular/cellular target(s) clinical status
vemurafenib BRAFv600e Approved for treatment of BRAFv600e 
mutation-positive melanoma.
PLX4720 BRAFv600e In preclinical studies, induces cell cycle 
arrest and apoptosis in BRAFv600e 
mutation-positive melanoma.
GDC-0879 BRAFv600e In preclinical studies, alters survival  
of cell line- and patient-derived BRAFv600e  
tumor cells.
AZ628 BRAFv600e, CRAFwT In preclinical studies, cytotoxic against 
BRAFv600e mutation-positive melanoma.
SB590885 BRAF, CRAF In preclinical studies, decreases growth  
of BRAF mutation-positive cell lines.
Sorafenib BRAFwT and v600e, CRAF, veGFR1,  
2 and 3, PDGFR, Flt3, p38, c-Kit, FGFR1
Shown to be ineffective as monotherapy  
in Phase I, II, and III trials.
Regorafenib c-Kit, veGFR2, BRAF Responses reported in Phase I colorectal 
cancer trial.
RAF265 RAF, veGFR Inhibits the growth of metastatic melanoma 
related to BRAFwT, c-KITL576P, NRASQ61R, 
and BRAFv600e/K mutations (Phase I/II).
Sunitinib Multi-kinase inhibition In Phase II trial, inconclusive responses 
reported in melanoma patients with Kit 
mutations.
NvP-BHG712 ephB4, veGFR2, CRAF, 
c-src and c-Abl kinases
Preclinical studies show inhibition of 
veGF-dependent angiogenesis.
ZM336372 CRAF BRAF, SAPK2/p38, PKA,  
PKC, p42 MAPK, CDK1, SAPK1/JNK
Preclinical status.
Perifosin Akt Not promising in a single dose Phase II trial.
Dabrafenib and trametinib BRAF, MeK Responses reported for combination 
therapy in a Phase II trial.
Bevacizumab  
and everolimus
Angiogenesis, mTOR well tolerated in the treatment of 
metastatic melanoma patients in a  
Phase II trial.
Sorafenib with temsirolimus  
or tipifarnib
Multiple pathway targeting Not promising in a Phase II trial.
1,3-bis(3,5-dichlorophenyl) 
urea (COH-SR4)
Inhibit proliferation and activates apoptosis  
through multiple pathway targeting
Promising in preclinical study.
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BRAF inhibitors and malignant melanoma
Clinical Medicine Insights: Dermatology 2013:6 5
F3C
CF3
HN
N O
O
H3C
H3C
H3C
H3C
H3C
H3CCH3
CH3
CH3
CH3
NH2
O
O O
O
Cl Cl
Cl
Cl
Cl
OH
N
RAF265 (CHIR-265)
Dabrafenib (GSK2118436) NVP-BHG712 Sorafenib
SunitanibAxitinibZM 336372
1,3-bis(3,5-dichlorophenyl)urea (COH-SR4) Regorafenib (BAY 73-4506)
Raf265 derivative Perifosine
F F
F
S
S
S
N
N
N
N
N
N N
N
N
N
N
N
N
N
N
H
H
N
H3C
F3C
CF3
CH3
CH3
CH3
CH3
CH3
H3C
F
H3C
HN
N O
OO
CF3CF3
CF3
O
O
O
O
O
O F O
O
O
OO−
N+
OP C18H35
N
H
N
H
N
H
N
H
N
H
NH
NH
N
H
N
H
N
H
H
N
H
N
H
N
H
N
H
N
N
H
N
N
N
Cl
N
N
H
Figure 2. Structures of kinase inhibitors identified as potential treatments for melanoma.
 inhibitor and thus exhibits anti-angiogenic activity.24 In 
a preclinical study it was found to inhibit the growth of 
advanced human melanoma tumors related to BRAFWT, 
c-KITL576P, NRASQ61R, or BRAFV600E/K mutations.25 The 
indolone derivative sunitinib, a kinase inhibitor, was 
found to respond well, but inconclusively, in melanoma 
patients with KIT mutations in a clinical study.26
NVP-BHG712 is an isopurine derivative and an orally 
effective inhibitor of multiple Eph receptor kinases. It 
is highly selective for EphB4, relatively less selective 
for VEGFR2, CRAF, c-src and c-Abl kinases, and dose 
dependently inhibits VEGF stimulated tissue formation 
and vascularization.27 ZM336372 is a potent, selective 
CRAF inhibitor and also inhibits BRAF, SAPK2/p38 
over 17 other protein kinases including PKA, PKC, 
p42 MAPK, CDK,1 and SAPK1/JNK.28 It markedly 
suppresses cellular proliferation and induces cell cycle 
inhibitors p21 and p18 in carcinoid tumor cells.29 In a 
phase II clinical trial perifosin, an  alkylphosphocholine 
analogue that targets Akt, did not show any promise 
for further development as a single dose therapy for 
metastatic melanoma, although no major toxicity was 
observed at the dose levels tested.30
Therapy Targeting Multiple pathways
The BRAF targeted drugs increasingly develop resis-
tance due to reactivation of the MAPK pathway. 
Moreover, secondary resistance develops almost inev-
itably, with reactivation of other components of the 
MAPK pathway or alternative pathway, including but 
not restricted to the PTEN/Akt pathway. This reflects 
that multiple pathways seem to be simultaneously of 
relevance in malignant melanoma and that simultane-
ous inhibition with active, low toxicity agents holds 
great promise in the primary treatment of malignant 
melanoma and in cases with secondary resistance to 
novel targeted agents. In this context, new candidate 
drugs capable of targeting multiple critical nodes of 
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melanoma signaling assume significance. Recent 
report from Beckman Research Institute, City of 
Hope National Medical Center: COH-SR4 (Fig. 2), 
a dichlorophenyl urea compound developed using an 
SAR strategy has been shown to inhibit proliferation 
and activates apoptosis in melanoma and has demon-
strated significant activity using in vitro cultured cells 
(NCI-60 panel), as well as both syngeneic and nude 
mouse models of melanoma.31
Combination therapy involving BRAF and MEK 
inhibitors may be more effective in the treatment of 
metastatic melanoma. The combination of dabrafenib 
and trametinib, targeting BRAF and MEK respectively, 
in patients with metastatic melanoma and BRAFV600E 
mutations has been shown to improve progression-free 
survival and provide a favorable safety margin in an 
open-label study.32 The combination of bevacizumab, 
an inhibitor of angiogenesis, and everolimus, an inhib-
itor of mTOR, was found to have moderate activity 
and was well tolerated in the treatment of patients with 
metastatic melanoma in a phase II trial of the Sarah 
Cannon Oncology Research Consortium.31 However, 
in another phase II trial, the combination of sorafenib 
with temsirolimus or tipifarnib did not show sufficient 
activity to justify further use. It was suggested based 
on these results that newer agents by characterization 
of the molecular targets in individual tumors would 
show greater promise.33
conclusion
Approved by FDA in 2011, vemurafenib (Zelboraf) 
is the first personalized targeted therapy for treat-
ment of metastatic melanoma that acts by selec-
tively inhibiting BRAFV600E. It causes programmed 
cell death specifically in BRAFV600E mutation-posi-
tive melanoma cell lines by interrupting the BRAF/
MEK/ERK pathway. About 60% of melanomas have 
this mutation and the FDA requires a positive test 
for the BRAFV600E mutation to be eligible for treat-
ment with this medication. This finding has opened 
a new avenue for the discovery of targeted drug 
therapies for melanoma based on the principles of 
pharmacogenomics.
Overall, safer and effective treatment options for 
melanoma are scarce. However, there is a rapid pace 
of discovery and development in the field of molec-
ular targeted drug therapies. It is a challenging task 
for biomedical scientists and clinicians to track and 
comprehend the volumes of information regarding the 
nature of molecular targets and the potential impact on 
therapeutic outcomes. As a result, it is important for 
interested groups to regularly communicate in the lit-
erature with reviews and editorials in order to provide 
concise summaries of the molecular and functional 
nature of targets and whether there are significant 
clinical trial findings which hold promise for positive 
patient outcomes.
Author contributions
Wrote the first draft of the manuscript: MOFK. Con-
tributed to the writing of the manuscript: MOFK, 
CLR. Jointly developed the structure and arguments 
for the paper: MOFK, CLR. Made critical revisions 
and approved final version: MOFK, CLR. All authors 
reviewed and approved of the final manuscript.
Funding
Author(s) disclose no funding sources.
competing Interests
Author(s) disclose no potential conflicts of interest.
Disclosures and ethics
As a requirement of publication the authors have pro-
vided signed confirmation of their compliance with 
ethical and legal obligations including but not lim-
ited to compliance with ICMJE authorship and com-
peting interests guidelines, that the article is neither 
under consideration for publication nor published 
elsewhere, of their compliance with legal and ethi-
cal guidelines concerning human and animal research 
participants (if applicable), and that permission has 
been obtained for reproduction of any copyrighted 
material. This article was subject to blind, indepen-
dent, expert peer review. The reviewers reported no 
competing interests. Provenance: the authors were 
invited to submit this paper.
References
1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new 
 targeted therapy. Nature. 2007;445(7130):851–7.
2. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51–65.
3. Eustace1 AJ, Mahgoub T, Tryfonopoulos D, O’Donovan N, Crown J. 
 Prospects for non-immunological molecular therapeutics in melanoma. 
J BUON. 2010;15(1):9–18.
4. National Cancer Institute’s “What you need to know about melanoma and 
other skin cancers.” US Department of Health and Human Services, NIH. 
Available at: http://www.cancer.gov/cancertopics/wyntk/skin.pdf. Accessed 
Dec 20, 2012.
BRAF inhibitors and malignant melanoma
Clinical Medicine Insights: Dermatology 2013:6 7
 5. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 
2009;27(1):3–9.
 6. FDA Approves Zelboraf (Vemurafenib) and companion diagnostic for 
BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer 
(press release). Genentech. Available at: http://www.gene.com/media/press-
releases/13567/2011-08-17/fda-approves-zelboraf-vemurafenib-and-co/. 
Accessed Dec 20, 2012.
 7. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for 
previously untreated metastatic melanoma. N Engl J Med. 2011;364(26): 
2517–26.
 8. Orgaz JL, Sanz-Moreno V. Emerging molecular targets in melanoma inva-
sion and metastasis. Pigment Cell Melanoma Res. 2013;26(1):39–57.
 9. Marone R, Erhart D, Mertz AC, et al. Targeting Melanoma with dual 
 phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol 
Cancer Res. 2009;7(4):601–13.
 10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human 
cancer. Nature. 2002;417(6892):949–54.
 11. Shaw RJ, Cantley LC. Ras, P1(3)K and mTOR signaling controls tumour 
cell growth. Nature. 2006;441(7092):424–30.
 12. Gray-Schopfer VC, Da Rocha DS, Marais R. The role of B-RAF in 
 melanoma. Cancer Metastasis Rev. 2005;24(1):165–83.
 13. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. 
Cancer Cell. 2004;6(4):313–9.
 14. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the 
RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 
2004;116(6):855–67.
 15. Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends 
Mol Med. 2012;18(1):27–35.
 16. Kelleher FC, McArthur GA. Targeting NRAS in melanoma. Cancer J. 
2012;18(2):132–6.
 17. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. 
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 
leads to different responses in melanoma and thyroid carcinoma cells. Mol 
Cancer Res. 2008;6(5):751–9.
 18. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer 
resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A. 2009; 
106(48):20411–6.
 19. Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF 
inhibitor GDC-0879 is predicted by BRAFV600E mutational status and 
sustained extracellular signal-regulated kinase/mitogen-activated protein 
kinase pathway suppression. Cancer Res. 2009;69(7):3042–51.
 20. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibi-
tion in cancer therapy. Expert Opin Ther Targets. 2007;11(12):1587–609.
 21. King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic thera-
peutic index for tumors expressing oncogenic BRAF by the kinase inhibitor 
SB-590885. Cancer Res. 2006;66(23):11100–5.
 22. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepato-
cellular carcinoma. Drugs. 2009;69(2):223–40.
 23. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): 
a new oral multikinase inhibitor of angiogenic, stromal and oncogenic 
receptor tyrosine kinases with potent preclinical antitumor activity. Int J 
Cancer. 2011;129(1):245–55.
 24. Mordant P, Loriot Y, Leteur C, et al. Dependence on phosphoinositide 
3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel 
RAF/VEGFR2 inhibitor, and RAD001 (everolimus) in combination. Mol 
Cancer Ther. 2010;9(2):358–68.
 25. Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced 
human melanoma tumors. Clin Cancer Res. 2012;18(8):2184–98.
 26. Minor DR, Kashani-Sabet M, Garrido M, O’Day SJ, Hamid O, Bastian BC. 
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer 
Res. 2012;18(5):1457–63.
 27. Martiny-Baron G, Holzer P, Billy E, et al. The small molecule specific 
EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. 
Angiogenesis. 2010;13(3):259–67.
 28. Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation of Raf by 
a novel Raf inhibitor. Chem Biol. 1999;6(8):559–68.
 29. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H. ZM336372, a Raf-1 
activator, suppresses growth and neuroendocrine hormone levels in carci-
noid tumor cells. Mol Cancer Ther. 2005;4(6):910–7.
 30. Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in 
previously untreated patients with metastatic melanoma. Invest New Drugs. 
2005;23(6):569–75.
 31. Singhal SS, Figarola J, Singhal J, et al. 1,3-bis(3,5-dichlorophenyl) urea 
compound ‘COH-SR4’ inhibits proliferation and activates apoptosis in mel-
anoma. Biochem Pharmacol. 2012;84(11):1419–27.
 32. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibi-
tion in Melanoma with BRAF V600 Mutations. N Engl J Med. 2012;367: 
1694–703.
 33. Hainsworth JD, Infante JR, Spigel DR, et al. Bevacizumab and everolimus 
in the treatment of patients with metastatic melanoma: a phase 2 trial of 
the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(17): 
4122–9.
 34. Margolin KA, Moon J, Flaherty LE, et al. Randomized phase II trial of 
sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma 
(S0438). Clin Cancer Res. 2012;18(4):1129–37.
